Lakefront Biotherapeutics NV GXE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €30.32
- Day Range
- €29.50–29.66
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 65.90M
- Market Cap
- €1.95B
- Volume/Avg
- — / 528
Key Statistics
- Price/Earnings (Normalized)
- 3.18
- Price/Sales
- 1.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 452
- Website
- https://www.lakefrontbio.com
Valuation
Metric | GXE |
|---|---|
Price/Earnings (Normalized) | 3.18 |
Price/Book Value | 0.60 |
Price/Sales | 1.98 |
Price/Cash Flow | 2.85 |
Price/Earnings
GXE
Financial Strength
Metric | GXE |
|---|---|
Quick Ratio | 32.65 |
Current Ratio | 32.84 |
Interest Coverage | — |
Quick Ratio
GXE
Profitability
Metric | GXE |
|---|---|
Return on Assets (Normalized) | 23.08% |
Return on Equity (Normalized) | 27.15% |
Return on Invested Capital (Normalized) | 27.09% |
Return on Assets
GXE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|C@#^>^ | LOCK|m^^@ | $139B | |||
| Moderna Inc MRNA | LOCK|qGY?rch | LOCK|$? | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|y&TlMY! | LOCK|&C@>G | $94B | |||
| argenx SE ADR ARGX | LOCK|kJW&RGs | LOCK|@Nr | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$%@dk< | LOCK|wj# | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^!>##%@ | LOCK|%>%C> | $30B | |||
| Incyte Corp INCY | LOCK|$j&hmRD | LOCK|nd> | $24B | |||
| BioNTech SE ADR BNTX | LOCK|BL$Xt?p | LOCK|&@> | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|y^TVYrF | LOCK|%SY#$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|g^hBB# | LOCK|Jqz | $15B |
United States